DIANA Biotechnologies – technology that raised EUR 3M in 3 years

DIANA Biotechnologies started as a project of a PhD. student at IOCB.  After less than 3 years of pre-seed incubation it developed into an independent biotech company, with their own laboratories, impressive portfolio of projects and products and stable venture capital funding. The technology originated from IOCB lab and its incubation has been supported by IOCB Tech, the Technology transfer office. The company has been established in summer of 2018 thanks to raising of EUR 3 m from BPD Partners investorsand it is further supported by i&i Prague team.

DIANA is a multi-well plate assay, where target protein is selectively captured to the solid carrier and then bound by a unique detection probe consisting of a small-molecule ligand linked to a DNA-oligonucleotide. Subsequently, the probe is detected and quantified by qPCR. For drug discovery, the assay utilizes competition between the probe and the test compounds to measure their binding affinity.

DIANA is a platform technology and its applications are effectively developed and used for both, super-sensitive Diagnostics (both for research use and clinical applications) and effective Drug discovery (high throughput screeningaffinity measurements and selectivity profilingassay development, lead compound optimization, ADME pharmacology).

To learn more about this technology: dianabiotech.com.